The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla has been helping extend the reach of affordable life-saving HIV/AIDS medications since 2001. The company supplies antiretroviral (ARV) medicines to 64 countries by mostly participating in the ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...

Cipla Q3 Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from ...

Cipla's North American business achieved a record $250 million revenue in Q1 FY25, a 13% year-on-year growth. The company's branded prescription business in India grew 10%, while overall India growth ...

With respect to generic Abraxane, Cipla has updated its launch guidance to late H2 FY26. The guidance assumes a six month lag in launch post U.S. Food and Drug Administration approval as company is ...

Cipla has announced that its emerging markets and European business unit has reached a new milestone by being recognized in the Asia Book of Records. During COPD Awareness Month, Cipla engaged 4,350 ...

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

Pharma major Cipla Ltd on Tuesday posted its highest-ever quarterly revenue and Ebitda margin, as robust sales in India, Europe and emerging markets outweighed weakness in its US business.